Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 9/20 | 0.53 |
| ▸ | TDO2 | P48775 | 9/20 | 0.53 |
| ▸ | IGFBP3 | P17936 | 1/20 | 0.38 |
| ▸ | TBXAS1 | P24557 | 6/20 | 0.36 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.36 |
| ▸ | BRD4 | O60885 | 1/20 | 0.36 |
| ▸ | CES2 | O00748 | 1/20 | 0.36 |
| ▸ | CES1 | P23141 | 1/20 | 0.36 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.36 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.36 |
| ▸ | PTGIS | Q16647 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18137636 | 0.86 | IDO1 (0.47) | IDO1TDO2TBXAS1PTGS1PTGS2 | |
| SCHEMBL18137634 | 0.85 | IDO1 (0.48) | IDO1TDO2TBXAS1PTGS1PTGS2 | |
| SCHEMBL20001809 | 0.83 | IDO1 (0.55) | IDO1TDO2CES2 | |
| SCHEMBL20002535 | 0.80 | IDO1 (0.38) | IDO1TDO2TBXAS1PTGS1PTGS2 | |
| SCHEMBL20002536 | 0.77 | IDO1 (0.41) | IDO1TDO2 | |
| SCHEMBL20002515 | 0.77 | IDO1 (0.44) | IDO1TDO2CYP19A1 | |
| SCHEMBL20002512 | 0.76 | IDO1 (0.50) | IDO1TDO2TBXAS1PTGS1PTGS2 | |
| SCHEMBL20002516 | 0.75 | KMO (0.42) | IDO1TDO2CYP19A1 | |
| SCHEMBL20001933 | 0.74 | TOP2A (0.37) | IDO1TDO2TBXAS1 | |
| SCHEMBL20001790 | 0.73 | IDO1 (0.50) | IDO1TDO2IGFBP3TBXAS1CYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180099939-A1 | COMPOUNDS AND METHODS FOR IDO AND TDO MODULATION AND INDICATIONS THEREFOR | PLEXXIKON INC. | 2018-04-12 | — | — | US | disclosed |
| US-20180099939-A1 | COMPOUNDS AND METHODS FOR IDO AND TDO MODULATION AND INDICATIONS THEREFOR | PLEXXIKON INC. | 2018-04-12 | — | — | US | disclosed |
| WO-2018057973-A1 | COMPOUNDS AND METHODS FOR IDO AND TDO MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. (US) | 2018-03-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180099939-A1 | COMPOUNDS AND METHODS FOR IDO AND TDO MODULATION AND INDICATIONS THEREFOR | IDO1, TDO2, IDO2 | IDO1 1/4885TDO2 2/4885IGFBP3 2106/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.